Retatrutide
Also Known As: LY-3437943, Triple-G, Retatrutide peptide, LY3437943, Triple agonist obesity drug, GIP GLP-1 glucagon triple agonist, Eli Lilly triple agonist, Triple incretin agonist, Retatrutide LY3437943, Tri-agonist obesity peptide, triple agonist, GLP-1/GIP/GCG, glucagon receptor, reta, ret
Retatrutide is a research-grade Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor targeting GIPR studied in Weight Loss & Metabolism research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Investigational - In active human clinical trials; not yet approved.
An investigational triple-agonist weight-loss peptide with strong early trial results.
At A Glance
| Category | Weight Loss & Metabolism |
|---|---|
| Compound Class | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect |
| Molecular Weight | 4731.3 Da |
| Amino Acid Sequence | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) |
| CAS Number | 2381089-83-2 |
| Half-Life | ~1 week |
| WADA Status | not_listed |
| Evidence Tier | Investigational |
Mechanism Of Action
It activates three different hormone receptors at once (GLP-1, GIP, and Glucagon). This not only halts appetite but forcefully increases the body's baseline calorie burn rate.
Studied For
- Obesity / overweight
- Type 2 diabetes
- Liver fat / MASLD / NAFLD
- Triple agonist weight loss
- GLP-1 GIP glucagon combined therapy
- Metabolic syndrome
- Insulin resistance
- HbA1c reduction
- Cardiovascular risk reduction
- Non-alcoholic steatohepatitis (NASH)
- Body weight reduction vs placebo
- Appetite suppression triple pathway
- Lean mass preservation during weight loss
- Obstructive sleep apnea in obesity
- extreme weight loss
- obesity
- liver fat reduction
- NAFLD
- metabolic rate increase
- appetite suppression
- lipid lowering
Reported Research Findings
A Phase 2 trial reported up to about 17.5 percent weight reduction at 24 weeks and more at 48 weeks; Phase 3 is ongoing.
Safety And Handling Notes
Dose-dependent gastrointestinal effects (nausea, vomiting, diarrhea), fatigue, mild heart-rate increases.
Investigational with no approved label or long-term safety data; theoretical thyroid C-cell and pancreatitis considerations under study. Research use only.
Regulatory Status
Investigational (Eli Lilly); Phase 3 TRIUMPH program -- TRIUMPH-1 topline results reported May 2026 (2,339 participants, 80 wk; -28.3% mean weight loss at 12 mg; all three doses met primary and key secondary endpoints vs placebo). As of August 2026 no NDA has been filed. Sponsor guidance is an obesity NDA submission in the second half of 2026 and a type 2 diabetes submission in early 2027; FDA has granted Fast Track designation for obesity. Not FDA-approved; non-trial material is research-use-only.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.